Guidelines for submitting samples and analytical data for methods validation.

Guidelines for submitting samples and analytical data for methods validation.

Bibliographic Details
Corporate Author:	Center for Drugs and Biologics (U.S.). Office of Drug Research and Review
Format:	Government Document eBook
Language:	English
Published:	Rockville, Md. : Food and Drug Administration, Center for Drugs and Biologics, Office of Drug Research and Review, [1987]
Subjects:	Drug approval > United States. Drugs > Analysis > Government policy > United States.
Online Access:	https://purl.fdlp.gov/GPO/LPS117249

Similar Items

Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances.
Published: (1987)

Guidance for industry : Q3A impurities in new drug substances.
Published: (2008)

Guidance for industry : M4, organization of the CTD.
Published: (2001)

Guidance for industry for the submission documentation for sterilization process validation in applications for human and veterinary drug products.
Published: (1994)

Guidance for industry : revising and ANDA labeling following revision of the RLD labeling.
Published: (2000)

Guidance for industry : ANDAs, impurities in drug products.
Published: (2005)

Guidance for industry : ANDAs, impurities in drug substances.
Published: (2009)

Guidance for industry : alternate source of the active pharmaceutical ingredient in pending ANDAs.
Published: (2000)

Food and Drug Amendments of 2022 : report of the Committee on Energy and Commerce (to accompany H.R. 7667).
Published: (2022)

FDA checkup : drug development and manufacturing challenges : hearing before the Subcommittee on Energy Policy, Health Care and Entitlements of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Thirteenth Congress, first session, December 12, 2013.
Published: (2014)

Guidance for industry and FDA staff : how to write a request for designation (RFD).
Published: (2005)

Guidebook for drug regulatory submissions /
by: Weinberg, Sandy, 1950-
Published: (2009)

Guidance for industry : changes to an approved NDA or ANDA, specifications, use of enforcement discretion for compendial changes.
Published: (2004)

Guidance for industry : changes to an approved NDA or ANDA, questions and answers.
Published: (2001)

Guidance for industry : major, minor, and telephone amendments to abbreviated new drug applications.
Published: (2001)

Guidance for industry : changes to an approved NDA or ANDA.
Published: (2004)

Guidance for industry : variations in drug products that may be included in a single ANDA.
Published: (1998)

Guidance for industry : formal meetings between the FDA and sponsors or applicants.
Published: (2009)

Guidance for FDA staff and industry : marketed unapproved drugs, compliance policy guide.
Published: (2006)

Guidance for industry : INDs for phase 2 and phase 3 studies, chemistry, manufacturing, and controls information.
Published: (2003)

Animal drug user fee agreements : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, first session, on examining animal drug user fee agreements, focusing on advancing animal health for the public health, February 27, 2013.
Published: (2014)

Guidance for industry : format and content for the CMC section of an annual report.
Published: (1994)

Guidance for industry : accelerated approval products, submission of promotional materials.
Published: (1999)

Guidance for industry : NDA's : impurities in drug substances.
Published: (2000)

Guidance for industry : referencing discontinued labeling for listed drugs in abbreviated new drug applications.
Published: (2000)

Guidance for industry : providing regulatory submissions in electronic format, general considerations.
Published: (1999)

Guidance for industry : M4E, the CTD, efficacy.
Published: (2001)

Guidance for industry : M4S, the CTD, safety.
Published: (2001)

Guidance for industry : M4S, the CTD, safety appendices.
Published: (2001)

Reviewer guidance : conducting a clinical safety review of a new product application and preparing a report on the review.
Published: (2005)

Guidance for industry : submitting marketing applications according to the ICH-CTD format, general considerations.
Published: (2001)

New drug approval : FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints : report to the Ranking Member, Committee on Finance, U.S. Senate.
Published: (2009)

Center for Drug Evaluation and Research update.

CDER ... report to the nation : improving public health through human drugs /
Published: (1998)

PDUFA V : medical innovation, jobs, and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, July 7, 2011.
Published: (2012)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act : report (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office).
Published: (2020)

Guidance for FDA reviews and sponsors : content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs).
Published: (2008)

Guidance for industry and FDA staff : submission and resolution of formal disputes regarding the timeliness of premarket review of a combination product.
Published: (2004)

Guidance for industry : M4Q, the CTD, quality.
Published: (2001)